Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges [Yahoo! Finance]
Elutia, Inc. - Class A (ELUT)
Company Research
Source: Yahoo! Finance
Adjusted Gross Margin: Increased to 61% from 60% a year ago. Bioenvelope Business Gross Margin: 68% for EluPro and CanGaroo. SimpliDerm Gross Margin: Operating Expenses: Increased to $13 million from $10 million, primarily due to noncash stock-based compensation. Net Income: Positive $1.3 million, influenced by noncash gain from warrant revaluation. Adjusted EBITDA: Loss of $2.9 million, up from $1.7 million loss a year ago. Cash Position: $25.7 million at the end of the quarter, bolstered by $13.8 million from warrant exercises. Warning! GuruFocus has detected 6 Warning Signs with ELUT. Release Date: November 14, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Elutia Inc ( NASDAQ:ELUT ) successfully launched its EluPro product line, marking a significant milestone with the first implant in September 2024. The SimpliDerm product line in breast reconstruction showed a 19% growth this quarter, indicating str
Show less
Read more
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Cardiac Resynchronization Therapy (CRT) Market Insights, Competitive Landscape and Market Forecast 2024-2030 [Yahoo! Finance]Yahoo! Finance
- Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.GlobeNewswire
- Elutia Inc. (NASDAQ: ELUT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.MarketBeat
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 [Yahoo! Finance]Yahoo! Finance
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025GlobeNewswire
ELUT
Sec Filings
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- ELUT's page on the SEC website